vs
AETHLON MEDICAL INC（AEMD）与ARTIVION, INC.（AORT）财务数据对比。点击上方公司名可切换其他公司
ARTIVION, INC.的季度营收约是AETHLON MEDICAL INC的1934.4倍（$116.0M vs $60.0K）。ARTIVION, INC.净利率更高（2.1% vs -2926.4%，领先2928.5%）。AETHLON MEDICAL INC自由现金流更多（$-2.0M vs $-7.9M）
AETHLON MEDICAL INC是一家临床阶段医疗科技企业，专注开发针对性治疗类医疗器械，核心产品血液净化器可从血液中去除有害病毒、肿瘤外泌体及其他病原体，业务聚焦传染病和肿瘤治疗赛道，主要市场覆盖北美地区。
Artivion, Inc.是一家专注于心血管移植领域的医疗企业，主要供应经深低温冷冻保存的人体组织，同时研发各类医疗器械。旗下核心产品包括经过特殊处理、去除多余细胞物质与抗原的人体心脏瓣膜，以及BioGlue手术粘合剂，可为临床诊疗提供专业支持。
AEMD vs AORT — 直观对比
营收规模更大
AORT
是对方的1934.4倍
$60.0K
净利率更高
AORT
高出2928.5%
-2926.4%
自由现金流更多
AEMD
多$5.9M
$-7.9M
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $60.0K | $116.0M |
| 净利润 | $-1.8M | $2.4M |
| 毛利率 | — | 63.1% |
| 营业利润率 | -3026.4% | 9.2% |
| 净利率 | -2926.4% | 2.1% |
| 营收同比 | — | 19.2% |
| 净利润同比 | 49.4% | 114.7% |
| 每股收益（稀释后） | $-10.05 | $0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AEMDAORT
| Q4 25 | — | $116.0M | ||
| Q3 25 | — | $113.4M | ||
| Q2 25 | — | $113.0M | ||
| Q1 25 | — | $99.0M | ||
| Q4 24 | $60.0K | $97.3M | ||
| Q3 24 | $95.1K | $95.8M | ||
| Q2 24 | — | $98.0M | ||
| Q1 24 | — | $97.4M |
净利润AEMDAORT
| Q4 25 | — | $2.4M | ||
| Q3 25 | — | $6.5M | ||
| Q2 25 | — | $1.3M | ||
| Q1 25 | — | $-505.0K | ||
| Q4 24 | $-1.8M | $-16.5M | ||
| Q3 24 | $-2.8M | $-2.3M | ||
| Q2 24 | — | $-2.1M | ||
| Q1 24 | — | $7.5M |
毛利率AEMDAORT
| Q4 25 | — | 63.1% | ||
| Q3 25 | — | 65.6% | ||
| Q2 25 | — | 64.7% | ||
| Q1 25 | — | 64.2% | ||
| Q4 24 | — | 63.2% | ||
| Q3 24 | — | 63.7% | ||
| Q2 24 | — | 64.6% | ||
| Q1 24 | — | 64.6% |
营业利润率AEMDAORT
| Q4 25 | — | 9.2% | ||
| Q3 25 | — | 11.1% | ||
| Q2 25 | — | 7.4% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | -3026.4% | 2.7% | ||
| Q3 24 | -3050.2% | 4.6% | ||
| Q2 24 | — | 6.6% | ||
| Q1 24 | — | 26.0% |
净利率AEMDAORT
| Q4 25 | — | 2.1% | ||
| Q3 25 | — | 5.7% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | -0.5% | ||
| Q4 24 | -2926.4% | -16.9% | ||
| Q3 24 | -2950.2% | -2.4% | ||
| Q2 24 | — | -2.2% | ||
| Q1 24 | — | 7.7% |
每股收益（稀释后）AEMDAORT
| Q4 25 | — | $0.06 | ||
| Q3 25 | — | $0.13 | ||
| Q2 25 | — | $0.03 | ||
| Q1 25 | — | $-0.01 | ||
| Q4 24 | $-10.05 | $-0.40 | ||
| Q3 24 | $-16.11 | $-0.05 | ||
| Q2 24 | — | $-0.05 | ||
| Q1 24 | — | $0.18 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.8M | $64.9M |
| 总债务越低越好 | — | $215.1M |
| 股东权益账面价值 | $4.3M | $448.2M |
| 总资产 | $6.5M | $884.8M |
| 负债/权益比越低杠杆越低 | — | 0.48× |
8季度趋势，按日历期对齐
现金及短期投资AEMDAORT
| Q4 25 | — | $64.9M | ||
| Q3 25 | — | $73.4M | ||
| Q2 25 | — | $53.5M | ||
| Q1 25 | — | $37.7M | ||
| Q4 24 | $4.8M | $53.5M | ||
| Q3 24 | $6.9M | $56.2M | ||
| Q2 24 | — | $55.0M | ||
| Q1 24 | — | $51.1M |
总债务AEMDAORT
| Q4 25 | — | $215.1M | ||
| Q3 25 | — | $214.9M | ||
| Q2 25 | — | $215.6M | ||
| Q1 25 | — | $314.7M | ||
| Q4 24 | — | $314.3M | ||
| Q3 24 | — | $314.0M | ||
| Q2 24 | — | $313.6M | ||
| Q1 24 | — | $313.3M |
股东权益AEMDAORT
| Q4 25 | — | $448.2M | ||
| Q3 25 | — | $438.7M | ||
| Q2 25 | — | $419.9M | ||
| Q1 25 | — | $294.3M | ||
| Q4 24 | $4.3M | $276.2M | ||
| Q3 24 | $6.0M | $304.7M | ||
| Q2 24 | — | $295.1M | ||
| Q1 24 | — | $295.0M |
总资产AEMDAORT
| Q4 25 | — | $884.8M | ||
| Q3 25 | — | $857.7M | ||
| Q2 25 | — | $838.4M | ||
| Q1 25 | — | $791.2M | ||
| Q4 24 | $6.5M | $789.1M | ||
| Q3 24 | $8.8M | $803.1M | ||
| Q2 24 | — | $789.5M | ||
| Q1 24 | — | $784.0M |
负债/权益比AEMDAORT
| Q4 25 | — | 0.48× | ||
| Q3 25 | — | 0.49× | ||
| Q2 25 | — | 0.51× | ||
| Q1 25 | — | 1.07× | ||
| Q4 24 | — | 1.14× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.06× | ||
| Q1 24 | — | 1.06× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.0M | $19.6M |
| 自由现金流经营现金流 - 资本支出 | $-2.0M | $-7.9M |
| 自由现金流率自由现金流/营收 | -3357.0% | -6.9% |
| 资本支出强度资本支出/营收 | 3.7% | 23.7% |
| 现金转化率经营现金流/净利润 | — | 8.06× |
| 过去12个月自由现金流最近4个季度 | — | $839.0K |
8季度趋势，按日历期对齐
经营现金流AEMDAORT
| Q4 25 | — | $19.6M | ||
| Q3 25 | — | $22.3M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $-17.0M | ||
| Q4 24 | $-2.0M | $10.1M | ||
| Q3 24 | $-2.2M | $11.5M | ||
| Q2 24 | — | $6.1M | ||
| Q1 24 | — | $-5.5M |
自由现金流AEMDAORT
| Q4 25 | — | $-7.9M | ||
| Q3 25 | — | $17.7M | ||
| Q2 25 | — | $11.7M | ||
| Q1 25 | — | $-20.6M | ||
| Q4 24 | $-2.0M | $8.7M | ||
| Q3 24 | — | $7.8M | ||
| Q2 24 | — | $3.6M | ||
| Q1 24 | — | $-9.1M |
自由现金流率AEMDAORT
| Q4 25 | — | -6.9% | ||
| Q3 25 | — | 15.6% | ||
| Q2 25 | — | 10.4% | ||
| Q1 25 | — | -20.8% | ||
| Q4 24 | -3357.0% | 9.0% | ||
| Q3 24 | — | 8.2% | ||
| Q2 24 | — | 3.7% | ||
| Q1 24 | — | -9.3% |
资本支出强度AEMDAORT
| Q4 25 | — | 23.7% | ||
| Q3 25 | — | 4.1% | ||
| Q2 25 | — | 2.9% | ||
| Q1 25 | — | 3.7% | ||
| Q4 24 | 3.7% | 1.5% | ||
| Q3 24 | 0.0% | 3.8% | ||
| Q2 24 | — | 2.6% | ||
| Q1 24 | — | 3.7% |
现金转化率AEMDAORT
| Q4 25 | — | 8.06× | ||
| Q3 25 | — | 3.42× | ||
| Q2 25 | — | 11.16× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -0.73× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AEMD
暂无分部数据
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
